These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25219563)

  • 21. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
    Vesikari T; Karvonen A; Lindblad N; Korhonen T; Lommel P; Willems P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2010 Jun; 29(6):e47-56. PubMed ID: 20508478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy.
    Cocchio S; Zanoni G; Opri R; Russo F; Baldo V;
    Hum Vaccin Immunother; 2016 Mar; 12(3):651-4. PubMed ID: 26528829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
    Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
    Haas H; Richard P; Eymin C; Fiquet A; Kuter B; Soubeyrand B
    Hum Vaccin Immunother; 2019; 15(4):778-785. PubMed ID: 30481110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Febrile seizures following measles and varicella vaccines in young children in Australia.
    Macartney KK; Gidding HF; Trinh L; Wang H; McRae J; Crawford N; Gold M; Kynaston A; Blyth C; Yvonne Z; Elliott E; Booy R; Buttery J; Marshall H; Nissen M; Richmond P; McInytre PB; Wood N;
    Vaccine; 2015 Mar; 33(11):1412-7. PubMed ID: 25444797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
    Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
    Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
    Shinefield H; Black S; Williams WR; Marchant C; Reisinger K; Stewart T; Meissner HC; Guerrero J; Klopfer SO; Xu J; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2005 Aug; 24(8):670-5. PubMed ID: 16094218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
    Shinefield H; Black S; Digilio L; Reisinger K; Blatter M; Gress JO; Brown ML; Eves KA; Klopfer SO; Schödel F; Kuter BJ
    Pediatr Infect Dis J; 2005 Aug; 24(8):665-9. PubMed ID: 16094217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial.
    Povey M; Henry O; Riise Bergsaker MA; Chlibek R; Esposito S; Flodmark CE; Gothefors L; Man S; Silfverdal SA; Štefkovičová M; Usonis V; Wysocki J; Gillard P; Prymula R
    Lancet Infect Dis; 2019 Mar; 19(3):287-297. PubMed ID: 30765242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of the use of MMRV in infants by pediatric infectious disease specialists with that of other affiliated providers.
    Ackerson BK; Li BH; Sy LS; Cheetham TC; Jacobsen SJ
    Vaccine; 2014 Apr; 32(16):1863-8. PubMed ID: 24508041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.
    Klein NP; Shepard J; Bedell L; Odrljin T; Dull P
    Vaccine; 2012 Jun; 30(26):3929-36. PubMed ID: 22504039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measles-containing vaccines and febrile seizures in children age 4 to 6 years.
    Klein NP; Lewis E; Baxter R; Weintraub E; Glanz J; Naleway A; Jackson LA; Nordin J; Lieu T; Belongia EA; Fireman B
    Pediatrics; 2012 May; 129(5):809-14. PubMed ID: 22473362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
    Bernstein HH; Eves K; Campbell K; Black SB; Twiggs JD; Reisinger KS; Conti RM; Flodmark CE; Rombo L; Klopfer S; Schödel F; Hartzel J; Kuter BJ;
    Pediatrics; 2007 Jun; 119(6):e1299-305. PubMed ID: 17502347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.
    Jacobsen SJ; Ackerson BK; Sy LS; Tran TN; Jones TL; Yao JF; Xie F; Cheetham TC; Saddier P
    Vaccine; 2009 Jul; 27(34):4656-61. PubMed ID: 19520201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra™) Compared to Separate MMR + V Vaccination.
    Bauchau V; Van Holle L; Cohen C
    Drug Saf; 2015 Nov; 38(11):1095-102. PubMed ID: 26251259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children.
    Gavrielov-Yusim N; Hoshen M; Singer SR; Neumann L; Balicer RD
    Vaccine; 2014 Sep; 32(39):4954-9. PubMed ID: 25075803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.